KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Esperion Therapeutics (ESPR) Equity Average (2016 - 2026)

Esperion Therapeutics filings provide 8 years of Equity Average readings, the most recent being -$376.7 million for Q4 2025.

  • On a quarterly basis, Equity Average rose 0.74% to -$376.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$376.7 million, a 0.74% increase, with the full-year FY2025 number at -$345.3 million, up 18.14% from a year prior.
  • Equity Average hit -$376.7 million in Q4 2025 for Esperion Therapeutics, up from -$442.4 million in the prior quarter.
  • In the past five years, Equity Average ranged from a high of -$182.8 million in Q1 2021 to a low of -$442.4 million in Q3 2025.
  • Median Equity Average over the past 5 years was -$342.2 million (2021), compared with a mean of -$338.3 million.
  • Biggest five-year swings in Equity Average: crashed 1727.85% in 2021 and later grew 12.26% in 2024.
  • Esperion Therapeutics' Equity Average stood at -$279.8 million in 2021, then dropped by 10.4% to -$308.9 million in 2022, then plummeted by 39.99% to -$432.5 million in 2023, then rose by 12.26% to -$379.5 million in 2024, then rose by 0.74% to -$376.7 million in 2025.
  • The last three reported values for Equity Average were -$376.7 million (Q4 2025), -$442.4 million (Q3 2025), and -$429.9 million (Q2 2025) per Business Quant data.